• Global vs. US Drug Pricing and Market Access

  • Oct 22 2024
  • Length: 54 mins
  • Podcast

Global vs. US Drug Pricing and Market Access

  • Summary

  • In this episode, we sit down with leading Market Access experts and members of ACCESS Forum to compare and contrast the drug pricing and access systems worldwide and the US. Our discussion delves into the distinct approaches taken by government vs. private markets, examining how regulatory environments, pricing controls, and reimbursement processes impact patient access to innovative therapies. We explore the challenges each approach faces, from cost pressures to affordability and access, and how they balance the interests of patients, governments, and pharmaceutical companies. Join us for a deep dive into how the global healthcare landscape is evolving and what lessons can be learned.

    Nikos Maniadakis, Ph.D., Professor, Health Management & Policy, University of West Attica
    Kimberly Baldwin, Senior Vice President, Value & Access, Ipsen Biopharmaceuticals
    Fauzea Hussain, Vice President, Public Policy, McKesson
    CMS (Centers for Medicare & Medicaid Services)
    European Medicines Agency
    Health technology assessments (HTAs)
    IRA (Inflation Reduction Act)
    Medicaid
    Medicare
    National Institute of Clinical Excellence (NICE)
    NCCN guidelines
    P&T committee (Pharmacy and Therapeutics Committee)
    PAP (Patient Assistance Program)
    Part B (Medicare)
    Part D (Medicare)
    Pharmacy Benefit Managers (PBMs)
    Quality-Adjusted Life Years
    Tricare
    Veterans Administration
    Medical terminology referenced in this episode:

    • Cell and gene therapies (CGT)
    • Insulin
    • Orphan drugs

    Questions or comments?
    Email us at comments@prescriptionforbetteraccess.com.




    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Global vs. US Drug Pricing and Market Access

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.